The SIRT5-SUCLG2 desuccinylation axis delays ovarian aging via a mitochondrial-epigenetic regulatory mechanism.
Boosting a protein linked to ovarian aging delayed reproductive decline in mice, opening avenues for fertility preservation.
SIRT5-mediated SUCLG2 desuccinylation at K93/K101 links mitochondrial TCA cycle activity to histone acetylation in aging ovaries; a SUCLG2 desuccinylation mutant gene therapy ameliorated ovarian aging in vivo. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- mechanistic study with single-cell transcriptomics and in vivo ovarian gene therapy
- Category
- rare_diseases
- Maturity
- Validated
- Journal
- Nat Commun
Why it surfaced
Nature Communications publication revealing a novel SIRT5-SUCLG2 mitochondrial-epigenetic axis in ovarian aging with in vivo gene therapy proof-of-concept, relevant to premature ovarian insufficiency treatment development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.